Shopping Cart 0
Cart Subtotal
USD 0

Male Hypogonadism - Pipeline Review, H1 2019

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Male Hypogonadism-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism-Pipeline Review, H1 2019, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape.

Male hypogonadism is a condition in which the body doesn't produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and untreated sleep apnea. Treatment includes hormone replacement.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Male Hypogonadism-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 1, 4, 7, 3, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).

- The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

Introduction

Male Hypogonadism-Overview

Male Hypogonadism-Therapeutics Development

Male Hypogonadism-Therapeutics Assessment

Male Hypogonadism-Companies Involved in Therapeutics Development

Male Hypogonadism-Drug Profiles

Male Hypogonadism-Dormant Projects

Male Hypogonadism-Discontinued Products

Male Hypogonadism-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Male Hypogonadism, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Male Hypogonadism, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Male Hypogonadism-Pipeline by Allergan Plc, H1 2019

Male Hypogonadism-Pipeline by Clarus Therapeutics Inc, H1 2019

Male Hypogonadism-Pipeline by Diurnal Group Plc, H1 2019

Male Hypogonadism-Pipeline by EndoCeutics Inc, H1 2019

Male Hypogonadism-Pipeline by Ferring International Center SA, H1 2019

Male Hypogonadism-Pipeline by Lipocine Inc, H1 2019

Male Hypogonadism-Pipeline by M et P Pharma AG, H1 2019

Male Hypogonadism-Pipeline by Medlab Clinical Ltd, H1 2019

Male Hypogonadism-Pipeline by Merck & Co Inc, H1 2019

Male Hypogonadism-Pipeline by Mereo Biopharma Group Plc, H1 2019

Male Hypogonadism-Pipeline by TesoRx Pharma LLC, H1 2019

Male Hypogonadism-Pipeline by Viramal Ltd, H1 2019

Male Hypogonadism-Dormant Projects, H1 2019

Male Hypogonadism-Discontinued Products, H1 2019

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Male Hypogonadism Therapeutic Products under Development, Key Players in Male Hypogonadism Therapeutics, Male Hypogonadism Pipeline Overview, Male Hypogonadism Pipeline, Male Hypogonadism Pipeline Assessment


Companies

Allergan Plc

Clarus Therapeutics Inc

Diurnal Group Plc

EndoCeutics Inc

Ferring International Center SA

Lipocine Inc

M et P Pharma AG

Medlab Clinical Ltd

Merck & Co Inc

Mereo Biopharma Group Plc

TesoRx Pharma LLC

Viramal Ltd

Male Hypogonadism-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism-Pipeline Review, H1 2019, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape.

Male hypogonadism is a condition in which the body doesn't produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and untreated sleep apnea. Treatment includes hormone replacement.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Male Hypogonadism-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 1, 4, 7, 3, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).

- The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents

Introduction

Male Hypogonadism-Overview

Male Hypogonadism-Therapeutics Development

Male Hypogonadism-Therapeutics Assessment

Male Hypogonadism-Companies Involved in Therapeutics Development

Male Hypogonadism-Drug Profiles

Male Hypogonadism-Dormant Projects

Male Hypogonadism-Discontinued Products

Male Hypogonadism-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Male Hypogonadism, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Male Hypogonadism, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Male Hypogonadism-Pipeline by Allergan Plc, H1 2019

Male Hypogonadism-Pipeline by Clarus Therapeutics Inc, H1 2019

Male Hypogonadism-Pipeline by Diurnal Group Plc, H1 2019

Male Hypogonadism-Pipeline by EndoCeutics Inc, H1 2019

Male Hypogonadism-Pipeline by Ferring International Center SA, H1 2019

Male Hypogonadism-Pipeline by Lipocine Inc, H1 2019

Male Hypogonadism-Pipeline by M et P Pharma AG, H1 2019

Male Hypogonadism-Pipeline by Medlab Clinical Ltd, H1 2019

Male Hypogonadism-Pipeline by Merck & Co Inc, H1 2019

Male Hypogonadism-Pipeline by Mereo Biopharma Group Plc, H1 2019

Male Hypogonadism-Pipeline by TesoRx Pharma LLC, H1 2019

Male Hypogonadism-Pipeline by Viramal Ltd, H1 2019

Male Hypogonadism-Dormant Projects, H1 2019

Male Hypogonadism-Discontinued Products, H1 2019

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Male Hypogonadism Therapeutic Products under Development, Key Players in Male Hypogonadism Therapeutics, Male Hypogonadism Pipeline Overview, Male Hypogonadism Pipeline, Male Hypogonadism Pipeline Assessment


Companies

Allergan Plc

Clarus Therapeutics Inc

Diurnal Group Plc

EndoCeutics Inc

Ferring International Center SA

Lipocine Inc

M et P Pharma AG

Medlab Clinical Ltd

Merck & Co Inc

Mereo Biopharma Group Plc

TesoRx Pharma LLC

Viramal Ltd